famotidine; ibuprofen · Horizon · NDA 022519
Duexis
Earliest generic entry, as listed
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022519 · 001 · RLD · discontinued | tablet, oral | 26.6MG;800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
Expired or delisted (5)
- US 8067451 · product, use U-1196 · 18 Jul 2026
- US 8309127 · product · 18 Jul 2026
- US 8318202 · product · 18 Jul 2026
- US 8449910 · product · 18 Jul 2026
- US 8501228 · use U-1196 · 18 Jul 2026